- Conditions
- Postmenopause, Hypertension, Pre-Hypertension
- Interventions
- Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 9
- States / cities
- Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Disease
- Interventions
- 0.625 mg of conjugated equine estrogen, 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, placebo tablets
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Premarin and Provera
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2002
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
- Conditions
- Menopause, Osteoporosis
- Interventions
- bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 64 Years · Female only
- Enrollment
- 1,886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
- Conditions
- Coronary Heart Disease
- Interventions
- Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 55 Years to 75 Years · Female only
- Enrollment
- 2,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2001
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Endometrial Hyperplasia, Osteoporosis
- Interventions
- Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 1,083 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more
- Conditions
- Cardiovascular Diseases, Coronary Disease, Heart Diseases, Coronary Arteriosclerosis
- Interventions
- Estrogens, Conjugated (USP), Medroxyprogesterone 17-Acetate, Placebo
- Drug
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 55 Years to 80 Years · Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Hot Flashes, Menopausal Symptoms
- Interventions
- conjugated estrogens, medroxyprogesterone
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more
- Conditions
- Vasomotor Symptoms Associated With Menopause
- Interventions
- Black cohosh, Multibotanical preparation, Multibotanical preparation + dietary soy counseling, Conjugated equine estrogen +/- medroxyprogesterone acetate
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 45 Years to 55 Years · Female only
- Enrollment
- 351 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Postmenopause
- Interventions
- Premarin/MPA 0.45 mg/1.5 mg
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 35 Years to 70 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Postmenopause
- Interventions
- Premarin/MPA, Provera 10 mg
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 35 Years to 70 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Menopause
- Interventions
- Estradiol , estriol , progesterone, estradiol, progesterone, estriol, progesterone, equine estrogens m-progesteroneacetate
- Drug
- Lead sponsor
- Jeanne Drisko, MD, CNS, FACN
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas